Finally, to optimize the possible beneficial effect of plasma, the more recent third generation trials are evaluating the CP infusion in particular populations of patients at high risk of development of severe or critical COVID-19, such as those with impaired humoral immunity, onco-hematological disorders or other severe cardiovascular or respiratory co-morbidities [68,69,70]. The gene discussed is CP; the disease is hematologic disorder.